financetom
Business
financetom
/
Business
/
Market Chatter: UBS Eyes Rewards to Bankers for Landing New Clients
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: UBS Eyes Rewards to Bankers for Landing New Clients
May 10, 2024 4:36 AM

07:17 AM EDT, 05/10/2024 (MT Newswires) -- UBS Group ( UBS ) is considering a plan to reward bankers who land rich clients for the investment bank's wealth management business, Bloomberg News reported Friday, citing people with knowledge of the matter.

The sources said that bankers who attract fresh clients in Asia and Europe would receive referral fees. Details remain under discussion and no decision has yet been made, the sources told Bloomberg.

UBS did not immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 29.28, Change: +0.31, Percent Change: +1.07

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Taiwan Semiconductor's Arizona Trials Match Taiwanese Plants' Productivity
Market Chatter: Taiwan Semiconductor's Arizona Trials Match Taiwanese Plants' Productivity
Sep 6, 2024
09:10 AM EDT, 09/06/2024 (MT Newswires) -- Taiwan Semiconductor Manufacturing ( TSM ) achieved productivity levels at its Arizona facility on par with its Taiwan-based plants, an indicator its big US project is on the right path, Bloomberg reported, citing a person familiar with the matter. In trial production at its first advanced US plant, the chipmaker's yield rate was...
Ventyx Biosciences Doses First Patient in Phase 2a Parkinson's Drug Trial
Ventyx Biosciences Doses First Patient in Phase 2a Parkinson's Drug Trial
Sep 6, 2024
09:00 AM EDT, 09/06/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Friday it has dosed the first patient in a phase 2a trial of its drug candidate VTX3232 for early-stage Parkinson's disease. The company said the study will assess the safety and tolerability of VTX3232, a selective NLRP3 inhibitor, over a 28-day treatment period involving about 10 patients....
Milestone Pharmaceuticals' Partner Ji Xing's Phase 3 Trial of Etripamil Meets Primary Endpoint
Milestone Pharmaceuticals' Partner Ji Xing's Phase 3 Trial of Etripamil Meets Primary Endpoint
Sep 6, 2024
09:08 AM EDT, 09/06/2024 (MT Newswires) -- Milestone Pharmaceuticals ( MIST ) said Friday that its licensing partner Ji Xing Pharmaceuticals reported that a phase 3 trial in China evaluating etripamil nasal spray to treat paroxysmal supraventricular tachycardia met its primary endpoint. Ji Xing said the results show a statistically significant greater proportion of patients who took etripamil converted PSVT...
Guidewire Q4 Beats Estimates, Revenue And ARR Surge
Guidewire Q4 Beats Estimates, Revenue And ARR Surge
Sep 6, 2024
Guidewire Software, Inc. ( GWRE ) shares are trading higher after the company reported fourth-quarter results on Thursday. Total revenue rose 8% Y/Y to $291.5 million, beating the consensus of $283.9 million. Subscription and support revenue increased by 29% Y/Y to $151.8 million, while license revenue decreased by 12% Y/Y to $88.9 million. Also, Services revenue fell by 2% to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved